科研成果 首页 > 科研成果

临床药学教研室

一、课题

1.      项目名称:组学大数据的质量控制与临床应用标准化研究(№: SS2015AA020104)

资助额:  1609万

经费来源:国家高技术研究发展“863”计划

起止年月:2015/01-2017/12

项目负责人:石乐明

2.      项目名称:新型体外Bio-PK/PD模拟系统的建立及其对SPRC代谢致毒的机理研究

资助额:70万元

经费来源:国家自然科学基金,81273584

起止年月:2013/01~2016/12

项目负责人:蔡卫民

3.      项目名称:表观遗传因子对大鼠生命周期中多器官基因表达的影响(№: 31471239)

资助额:  100万

经费来源:国家自然科学基金面上项目

起止年月:2015/01-2018/12

项目负责人:石乐明

4.      项目名称:PBPK建模预测CYP3A5基因型对五酯胶囊和他克莫司药动相互作用的影响(№: 81473409)

资助额:  68.0万

经费来源:国家自然科学基金面上项目

起止年月:2015/01-2018/12

项目负责人:相小强

5.      项目名称:基于OATPs/UGT1A1/MRPs调控研究何首乌对胆红素代谢转运的影响及其肝毒性机理”(No. 81374051)

资助额: 75万

经费来源:国家自然科学基金面上项目

起止年月:2014/01-2017/12

项目负责人:马国

6.      项目名称:K-RAS 基因突变对ABC 转运体介导的肿瘤多药耐药的影响及分子机制研究(№: 81102459)

资助额:  22.0万

经费来源:国家自然科学基金

起止年月:2012/01-2014/12

项目负责人:郑媛婷

7.      项目名称:K-ras基因突变介导胰腺癌对吉西他滨耐药的机理研究

资助额:12万元

经费来源:教育部博士点基金(博导类),20130071110069

起止年月:2014/1~2016/12

项目负责人:蔡卫民

8.      项目名称:复旦-张江临床基因组学联合研究中心

资助额:  1500万

经费来源:上海张江转化医学研发中心

起止年月:2014/01-2018/12

项目负责人:石乐明

9.      项目名称:基因组学数据的质量控制及高性能计算技术在医学大数据产业中的应用(№: 14X I-2-02)

资助额:  60万

经费来源:上海市经济和信息化委员会2014年度引进技术的吸收与创新计划项目

起止年月:2014/08-2016/12

项目参与人:石乐明

10.  项目名称:基于OATP1B1/UGT1A1/ MRP2调控研究中药(何首乌)对胆红素代谢转运的影响及其肝毒性机制”(No. 20520133531)

资助额: 40万

经费来源:教育部中央高校基本科研业务费青年教师能力提升项目

起止年月:2013/01-2016/12

项目负责人:马国

11.  项目名称:阿米洛利增敏EGFR TKI的机理研究(№: 20520133186)

资助额:  20.0万

经费来源:中央高校青年教师科研能力提升项目

起止年月:2013/01-2013/12

项目负责人:郑媛婷

12.  项目名称:一种新型超声波水的安全性评价与通便功能研究”(项目代码CXF0080111,校内结算凭证帐号 SGF301171)

资助额: 7万

经费来源:无锡天夏超声设备股份有限公司横向课题

起止年月:2014/11-2015/04

项目负责人:马国

16.项目名称:上海市基层医疗机构实施基本药物制度成效的评价体系研究(№: 20134y149)

资助额:  2.0万

经费来源:上海市卫计委青年科研基金

起止年月:2014/01-2016/12

项目负责人:洪兰

17.项目名称:中国药学会,国家药品应急体系建设

   起始年月:2011年

项目负责人:叶桦

18.项目名称:国内各省基本药物招标采购的研究

   起始年月:2012年  

项目负责人:叶桦

19.项目名称:药品零售企业药品消费者的调研 

   起始年月:2012年

项目负责人:叶桦

20.项目名称:上海市药品安全现状报告研究 

   起始年月:2013年

项目负责人:叶桦

21.项目名称:上海市基层医疗机构实施基本药物制度成效的评价体系研究

   起始年月:2013年

项目负责人:叶桦

22.项目名称:张江生物医药产业发展规划研究

   起始年月:2015年

项目负责人:叶桦

13.  项目名称:临床药学专业课程与教学体系研究

资助额: 3000元

经费来源:中国高等教育学会医学教育专业委员会药学教育研究会2010年重点项目

起止年月:2011/01~2012/12

项目负责人:蔡卫民

14.  项目名称:《临床药物治疗学》优质课程建设

资助额:10万元

经费来源:2012上海市研究生教育创新计划实施项目(第一批),SHGS-KC-2011001

起止年月:2012/01~2012/12

项目负责人:蔡卫民

15.  项目名称:基于标准化病人的临床药学实践能力考核指标的研究(№: yjzw2015A03)

资助额:  0.8万

经费来源:药学硕士专业学位研究生教育教学改革课题(全国药学专业学位研究生教育指导委员会)

起止年月:2015/04 – 2015/03

项目负责人:相小强

 


二、论文发表

1.      蔡卫民,翟晓波,何志高,文传民,张鹏. 临床药学服务补偿机制初探[J].中国医院药学杂志, 2011, 31(1):1~4.

2.      张琳,马国,蔡卫民,张鹏. 炔丙基半胱氨酸的HPLC测定及其大鼠在体肠吸收[J].中国医药工业杂志, 2011,42(5):370~3.

3.      Chen B, Zhang WX, Gu ZD, Li J, Zhang YX, Cai WM. Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipient[J]. Eur J Clin Pharmacol, 2011, 67(6): 601~612.

4.      徐婷,蔡卫民. 我国药事服务费研究进展[J].中国药师, 2011, 14(8): 1201~3. 通信作者

5.      Carpi FM, Xu JL, Vincenzetti S, Vita A, Cai WM, Napolioni V. Rapid Allele-Specific PCR method for CDA 79A > C (K27Q) genotyping: A useful pharmacogenetic tool and world-wide polymorphism distribution[J]. Clinica Chimica Acta, 2011, 412(23~24): 2237~40.

6.      徐婷,翟晓波,何志高,蔡卫民,张鹏,文传民. 应用智能化用药安全警示互动系统干预肾内科药物不良事件效果评价[J].药物流行病学杂志, 2012, 21(3):122~126.

7.      Xu J, Zhou Y, Zhang J, Chen Y, Zhuang R, Liu T, Cai W. High incidence of severe neutropenia after gemcitabine-based chemotherapy in Chinese cancer patients with CDA 79A>C mutation[J]. Clinica Chimica Acta, 2012, 413(15~16): 1284~1287. 通信作者

8.      张金莲,刘洪瑞,毛煌,郑源婷,蔡卫民. 益母草碱极其代谢物在大鼠体内的毒代动力学研究[J]. 中国医药工业杂志, 2012, 43(6): 451~454. 通信作者

9.      马国,侯爱君,张鹏,郑媛婷,林佳媛,蔡卫民. 临床药学教育新模式的探索与实践[J].中国临床药学杂志, 2012, 21(6): 377~82. 通信作者

10.  Zhou H, Meng S,  Zhao J, Dong J,  Xu A,  Wang F, Guzalnur T,  Xin J,  Zhang J  Wang J, Cai W.  Influence of genetic and non-genetic factors on the plasma concentrations of the clopidogrel metabolite (SR26334) among Chinese patients[J]. Clinica Chimica Acta,  2013, 513:50~53. 通信作者

11.  马国,蔡卫民. 美国Pharm.D.教育及其对我国临床药学教育的启示[J].中国临床药学杂志, 2013, 22 (6):379-384. 通信作者

12.  母辉,汪建玲,丁永刚,曲鹏,蔡卫民. 种族敏感性临床试验的样本量计算方式探讨[J].中国卫生统计, 2014, 31(1): 31~33. 通信作者

13.  Zhu Q, Zhang JL, Yang P, Tan Bo, Liu XH, Zheng YT, Cai WM, Zhu YZ. Characterization of Metabolites of Leonurine(SCM-198) in Rats after Oral Administration by Liquid Chromatography/ Tandem Mass Spectrometry and NMR Spectrometry[J]. The Scientific World Journal, 2014.doi:10.1155/2014/947946.

14.  孟现民,尹康,董平,蔡卫民. 治疗药物监测和基因型为指导的依非韦伦个体化用药研究进展[J].世界临床药物, 2014,35(5): 257-263. 通信作者

15.  孟现民,尹康,董平,卢洪洲. 基因多态性与利福平对依非韦伦血药浓度和疗效的影响[J]. 世界临床药物, 2014; 15(5).

16.  Tan B, Cai W, Zhang J, Zhou N, Ma G, Yang P, Zhu Q, Zhu Y. Identification of UDP-glucuronosyltransferase isoforms responsible for leonurine glucuronidation in human liver and intestinal microsomes[J]. Xenobiotica, 2014, 44(5): 775~784. 共同第一作者

17.  Kang Yin, Xianmin Meng, Ping Dong, Tianran Ding, Li Shen, Li Zhang, Renfang Zhang,Weimin Cai, Hongzhou Lu. A simple, rapid, economical, and practical method for the determination of efavirenz in plasma of Chinese AIDS patients by reverse phase high-performance liquid chromatography with ultraviolet detector[J]. BioScience Trends, 2014, 8(4):227-234.

18.  Guo Ma, Lin Zhang, Peng Zhang, Xingfei Bao, Ning Zhou, Qingling Shi, Yuanting Zheng, Hongrui Liu, Fengjiao Bu, Ying Zhang, Wenjie Huang, Fen Wang, Yizhun Zhu, and Weimin Cai. Physicochemical characteristics and gastrointestinal absorption behaviors of S-propargyl-cysteine, a potential new drug candidate for cardiovascular protection and antitumor treatment[J]. Xenobiotica, 2015, 45(4): 322-34. 通信作者

19.  Meng X, Yin K, Wang J, Dong P, Liu L, Shen Y, Shen L, Ma Q, Lu H, Cai W. Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection[J]. PLoS One, 2015, 10(6):e0130583. doi: 10.1371/journal.pone.0130583.通信作者

20.  周忆男,蔡卫民. 上海市部分医疗机构药房托管调研与可行性分析[J]. 中国药师, 2015,  18(3): 446~8. 通信作者

21.  Zhang W, Yu Y, Hertwig F, Thierry-Mieg J, Zhang W, Thierry-Mieg D, Wang J, Furlanello C, Devanarayan V, Cheng J, Deng Y, Hero B, Hong H, Jia M, Li L, Lin SM, Nikolsky Y, Oberthuer A, Qing T, Su Z, Volland R, Wang C, Wang MD, Ai J, Albanese D, Asgharzadeh S, Avigad S, Bao W, Bessarabova M, Brilliant MH, Brors B, Chierici M, Chu TM, Zhang J, Grundy RG, He MM, Hebbring S, Kaufman HL, Lababidi S, Lancashire LJ, Li Y, Lu XX, Luo H, Ma X, Ning B, Noguera R, Peifer M, Phan JH, Roels F, Rosswog C, Shao S, Shen J, Theissen J, Tonini GP, Vandesompele J, Wu PY, Xiao W, Xu J, Xu W, Xuan J, Yang Y, Ye Z, Dong Z, Zhang KK, Yin Y, Zhao C, Zheng Y, Wolfinger RD, Shi T, Malkas LH, Berthold F, Wang J, Tong W, Shi L, Peng Z, Fischer M. Comparison of RNA-seq and microarray-based models for clinical endpoint prediction[J]. Genome Biol, 2015,16:133. 共同通信作者;学生为共同第一作者 SCI, IF: 10.81

22.  Du T, Yang L, Luo H, Zhou P, Mei H, Xuan J, Xing Q, Ning B, Mendrick DL, Shi L. HLADR: a database system for enhancing the discovery of biomarkers for predicting human leukocyte antigen-mediated idiosyncratic adverse drug reactions[J]. Biomarkers in Medicine, 2015. [Epub ahead of print]  共同通信作者;学生为共同第一作者

23.  Su Z, Labaj P, Li S, Kreil DP, Mason CE, Shi L. A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequence Quality Control consortium[J]. Nature Biotechnology, 2014, 32(9), 903-14. ESI Hot Paper; ESI Highly Cited Paper. 共同通信作者

24.  Yu Y, Fuscoe JC, Zhao C, Guo C, Jia M, Qing T, Bannon DI, Lancashire L, Bao W, Du T, Luo H, Su Z, Jones WD, Moland CL, Branham WS, Qian F, Ning B, Li Y, Hong H, Guo L, Mei N, Shi T, Wang KY, Wolfinger RD, Nikolsky Y, Walker SJ, Duerksen-Hughes P, Mason CE, Tong W, Thierry-Mieg J, Thierry-Mieg D, Shi L, Wang C. A rat RNA-Seq transcriptomic Bodymap across 11 organs and 4 developmental stages[J]. Nature Communications, 2014, 5:3230. 共同通信作者;学生为共同第一作者

25.  Yu Y, Zhao C, Su Z, Wang C, Fuscoe JC, Tong W, Shi L. Comprehensive RNA-Seq transcriptomic profiling across 11 organs, 4 ages, and 2 sexes of Fischer 344 rats[J]. Scientific Data, 2014, 1:140013  通信作者;学生为第一作者

26.  Xu J, Su Z, Hong H, Thierry-Mieg J, Thierry-Mieg D, Kreil DP, Mason CE, Tong W, Shi L. Cross-platform ultradeep transcriptomic profiling of human reference RNA samples by RNA-Seq[J]. Scientific Data, 2014, 1:140020共同通信作者

27.  Qing T, Yu Y, Du T, Shi L. mRNA enrichment protocols determine the quantification characteristics of external RNA spike-in controls in RNA-Seq studies[J]. Science China Life Science, 2013, 56(2):134-42 通信作者;学生为第一作者

28.  Xuan J, Yu Y, Qing T, Guo L, Shi L. Next-generation sequencing in the clinic: promises and challenges[J]. Cancer Letters, 2013, 340, 284-295. 通信作者;复旦合作者为第一作者

29.  Wen Z, Wang Z, Wang S, Ravula R, Yang L, Xu J, Wang C, Zuo Z, Chow MSS, Shi L, Huang Y. Discovery of molecular mechanisms of traditional Chinese medicinal formula Si-Wu-Tang using gene expression microarray and connectivity map[J]. PLoS ONE, 2011, 6(3): e18278. 共同通信作者

30.  Peifer M, Hertwig F, Roels F, …, Shi L, …, Westermann F, Thomas RK, Fischer M. Telomerase activation by genomic rearrangements in high-risk neuroblastoma[J]. Nature, 2015, 526(7575):700-704.

31.  Boutrin MC, Yu Y, Wang C, Aruni W, Dou Y, Shi L, Fletcher HM. A putative TetR regulator is involved in nitric oxide stress resistance in Porphyromonas gingivalis[J]. Molecular Oral Microbiology, 2015. doi: 10.1111/omi.12128. [Epub ahead of print]

32.  Luo H, Ye H, Ng H, Shi L, Tong W, Mattes W, Mendrick D, Hong H. Understanding and predicting binding between human leukocyte antigens (HLAs) and peptides by network analysis[J]. BMC Bioinformatics, 2015, 16 Suppl 13:S9. 

33.  Luo H, Ye H, Ng HW, Shi L, Tong W, Mendrick DL, Hong H. Machine Learning Methods for Predicting HLA-Peptide Binding Activity[J]. Bioinformatics and Biology Insights, 2015; 11(9) (Suppl 3):21-9.

34.  Li Z, Qin T, Wang K, Hackenberg M, Yan J, Gao Y, Yu LR, Shi L, Su Z, Chen T. Integrated microRNA, mRNA, and protein expression profiling reveals microRNA regulatory networks in rat kidney treated with a carcinogenic dose of aristolochic acid[J]. BMC Genomics, 2015, 8(16):365.

35.  Wang C, Gong B, Bushel PR, Thierry-Mieg J, Thierry-Mieg D, Xu J, Fang H, Hong H, Shen J, Su Z, Meehan J, Li X, Yang L, Li H, Labaj PP, Kreil DP, Megherbi D, Gaj S, Caiment F, van Delft J, Kleinjans J, Scherer A, Devanarayan V, Wang J, Yang Y, Qian HR, Lancashire LJ, Bessarabova M, Nikolsky Y, Furlanello C, Chierici M, Albanese D, Jurman G, Riccadonna S, Filosi M, Visintainer R, Zhang KK, Li J, Hsieh JH, Svoboda DL, Fuscoe JC, Deng Y, Shi L, Paules RS, Auerbach SS, Tong W. The concordance between RNA-seq and microarray data depends on chemical treatment and transcript abundance[J]. Nature Biotechnology, 2014, 32(9): 926-932. ESI Highly Cited Paper 

36.  Li S, Labaj PP, Zumbo P, Sykacek P, Shi W, Shi L, Phan J, Wu PY, Wang M, Wang C, Thierry-Mieg D, Thierry-Mieg J, Kreil DP, Mason CE. Detecting and correcting systematic variation in large-scale RNA sequencing data[J]. Nature Biotechnology, 2014, 32(9): 888-895.

37.  Munro SA, Lund SP, Pine PS, Binder H, Clevert DA, Conesa A, Dopazo J, Fasold M, Hochreiter S, Hong H, Jafari N, Kreil DP, Labaj PP, Li S, Liao Y, Lin SM, Meehan J, Mason CE, Santoyo-Lopez J, Setterquist RA, Shi L, Shi W, Smyth GK, Stralis-Pavese N, Su Z, Tong W, Wang C, Wang J, Xu J, Ye Z, Yang Y, Yu Y, Salit M. Assessing technical performance in differential gene expression experiments with external spike-in RNA control ratio mixtures[J]. Nature Communications, 2014, 5:5125.

38.  Su Z, Fang H, Hong H, Shi L, Zhang W, Zhang W, Zhang Y, Dong Z, Lancashire LJ, Bessarabova M, Yang X, Ning B, Gong B, Meehan J, Xu J, Ge W, Perkins R, Fischer M, Tong W. An investigation of biomarkers derived from legacy microarray data for their utility in the RNA-Seq era[J]. Genome Biology, 2014,15:3273.

39.  Pandey GK, Mitra S, Subhash S, Hertwig F, Kanduri M, Mishra K, Fransson S, Ganeshram A, Mondal T, Bandaru S, ?stensson M, Akyürek LM, Abrahamsson J, Pfeifer S, Larsson E, Shi L, Peng Z, Fischer M, Martinsson T, Hedborg F, Kogner P, Kanduri C. The risk-associated long noncoding RNA NBAT-1 controls neuroblastoma progression by regulating cell proliferation and neuronal differentiation[J]. Cancer Cell, 2014, 26(5): 722-737.

40.  Gong B, Wang C, Su Z, Hong H, Thierry-Mieg J, Thierry-Mieg D, Sansone SA, Rocca-Serra P, Shi L, Auerbach S, Tong W, Xu J. Transcriptomic profiling of rat liver samples in a comprehensive study design by RNA-Seq[J]. Scientific Data, 2014, 1:140021.

41.  Hatzis C, Bedard PL, Juul Birkbak N, Beck AH, Aerts HJ, Stern DF, Shi L, Clarke R, Quackenbush J, Haibe-Kains B. Enhancing reproducibility in cancer drug screening: how do we move forward? [J]. Cancer Research, 2014, 74(15): 4016-4023.

42.  Luo H, Zhang P, Huang H, Huang J, Kao E, Shi L, He L, Yang L. DDI-CPI, a server that predicts drug-drug interactions through implementing the chemical-protein interactome[J]. Nucleic Acids Research, 2014, 42(Web Server issue): W46-52.

43.  Chen M, Tung CW, Shi Q, Guo L, Shi L, Fang H, Borlak J, Tong W. A testing strategy to predict risk for drug-induced liver injury in humans using high-content screen assays and the ‘rule-of-two’ model[J]. Archives of Toxicology, 2014, 88(7): 1439-1449.

44.  Ning B, Su Z, Mei N, Hong H, Deng H, Shi L, Fuscoe JC, Tolleson WH. Toxicogenomics and cancer susceptibility: advances with next-generation sequencing[J]. Journal of Environmental Science and Health Part C Environmental Carcinogenesis & Ecotoxicology Reviews, 2014, 32(2): 121-158.

45.  Blomquist TM, Crawford EL, Lovett JL, Yeo J, Stanoszek LM, Levin A, Li J, Lu M, Shi L, Muldrew K, Willey JC. Targeted RNA-sequencing with competitive multiplex-PCR amplicon libraries[J]. PLoS ONE, 2013, 8(11):e79120.

46.  Xie C, Wang Z, Wang C, Xu J, Wen Z, Wang H, Shi L, Chow MS, Huang Y, Zuo Z. Utilization of gene expression signature for quality control of traditional Chinese medicine formula Si-Wu-Tang[J]. The AAPS Journal, 2013, 15(3): 884-892.

47.  Liu M, Fan J, Wang S, Wang Z, Wang C, Zuo Z, Chow MS, Shi L, Wen Z, Huang Y. Transcriptional profiling of Chinese medicinal formula Si-Wu-Tang on breast cancer cells reveals phytoestrogenic activity[J]. BMC Complementary and Alternative Medicine, 2013, 13(1):11.

48.  Yang L, Wang K, Chen J, Jegga AG, Luo H, Shi L, Wan C, Guo X, Qin S, He G, Feng G, He L. Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome-clozapine-induced agranulocytosis as a case study[J]. PLoS Computational Biology, 2011,7(3): e1002016.

49.  王可鉴, 石乐明, 贺林, 张永祥, 杨仑. 中国药物研发的新机遇:基于医药大数据的系统性药物重定位[J]. 科学通报, 2014, 59(18), 1790-1796.

50.  Chen W, Yeo SC, Elhennawy MG, Xiang X, Lin HS.Determination of naturally occurring resveratrol analog trans-4,4'-dihydroxystilbene in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study[J]. Anal Bioanal Chem, 2015.

51.  Xiang X, Backman JT, Neuvonen PJ, Niemi M. Gender, but not CYP7A1 or SLCO1B1 polymorphism, affects the fasting plasma concentrations of bile acids in human beings[J]. Basic Clin Pharmacol Toxicol, 2012, 110(3):245-52.

52.  Xiang X, Vakkilainen J, Backman JT, Neuvonen PJ, Niemi M. No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid[J]. Eur J Clin Pharmacol, 2011, 67(11):1159-67.

53.  卜凤娇,蒋 品,张洪艳,相小强. 以五味子为例的多来源药材品种鉴别研究进展[J].时珍国药, 2015, 11.

54.  Zhou N#, Zheng YT# (co-first author), Xing JF, Yang HY, Chen HM, Xiang XQ, Liu J, Tong SS, Zhu B, Cai WM. Application of a new dynamic model to predict the in vitro intrinsic clearance of tolbutamide using rat microsomes encapsulated in a Fab hydrogel[J]. Drug Metabolism and Disposition, 2015. pii: dmd.115.066092. (SCI, IF: 3.420)

55.  Zheng YT, Qing T, Song YJ, Zhu JH, Yu Y, Shi WW, Pusztai L, Shi LM. Standardization efforts enabling next-generation sequencing and microarray based biomarkers for precision medicine[J]. Biomarkers in Medicine, 2015, 9(11): 1265-72. (SCI, IF: 2.838)

56.  Zheng YT, Yang HY, Li T, Zhao B, Shao TF, Xiang XQ, Cai WM. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway[J]. Acta Pharmacologica Sinica, 2015, 36(5): 614-26. (SCI, IF: 2.912)

57.  Shao TF, Zheng YT* (corresponding author) Zhao B, Li T, Cheng KG, Cai WM. Recombinant expression of different mutant K-ras gene in pancreatic cancer Bxpc-3 cells and its effects on chemotherapy sensitivity[J]. Science China Life Sciences, 2014, 57(10): 1011-7. (SCI, IF: 1.688)

58.  Yang HY#, Zheng YT# (co-first author), Zhao B, Shao TF, Shi QL, Zhou N, Cai WM. Encapsulation of liver microsomes into a thermosensitive hydrogel for characterization of drug metabolism and toxicity[J]. Biomaterials, 2013, 34(38): 9770-8. (SCI, IF: 8.312)

59.  Zheng YT# (co-first author), Xu JL#, Ma G, Zhang JL, Zhu Q, Liu HR, Zhang P, Zhu YZ, Cai WM. Bioavailability and pharmacokinetics of S-propargyl-L-cysteine, a novel cardioprotective agent, after single and multiple doses in Beagle dogs[J]. Xenobiotica, 2012, 43(3): 304-9. (SCI, IF: 1.984)

60.  Zheng YT, Zhu JH, Ma G, Zhu Q, Yang P, Tan B, Zhang JL, Shen HX, Xu JL, Zhu YZ, Cai WM. http://www.ncbi.nlm.nih.gov/pubmed/22543704Preclinical assessment of the distribution, metabolism, and excretion of S-propargyl-cysteine, a novel H2S donor, in Sprague-Dawley rats[J]. Acta Pharmacologica Sinica, 2012, 33(6): 839-44. (SCI, IF: 2.354)

61.  Zheng YT# (co-first author), Liu HR#, Ma G, Yang P, Zhang L, Gu Y, Zhu Q, Shao TF, Zhang P, Zhu YZ, Cai1 WM. Determination of S-propargyl-cysteine in rat plasma by mixed-mode reversed-phase and cation-exchange HPLC-MS/MS method and its application to pharmacokinetic studies[J]. Journal of Pharmaceutical and Biomedical Analysis, 2011, 54: 1187-91. (SCI, IF:2.967)

62.  Zheng YT# (co-first author), Zhou F#, Wu XL, Wen XZ, Li YN, Yan B, Zhang JW, Hao G, Ye WC, Wang GJ. 23-hydroxybetulinic acid from Pulsatillachinensis (Bunge) Regel synergizes the antitumor activities of doxorubicin in vitro and in vivo[J]. Journal of Ethnopharmacology, 2010, 128(3): 615-22. (SCI, IF: 2.466)

63.  SEQC/MAQC-III Consortium (Yuanting Zheng was listed as one of 168 coauthors). A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Quality Control Consortium[J]. Nature Biotechnology, 2014, 32(9): 903-14. (SCI, IF: 41.514)

64.  Zhou F, Hao G, Zhang J, Zheng Y, Wu X, Hao K, Niu F, Luo D, Sun Y, Wu L, Ye W, Wang G. Protective effect of 23-hydroxybetulinic acid on doxorubicin-induced cardiotoxicity: a correlation with the inhibition of carbonyl reductase-mediated metabolism[J]. British Journal of Pharmacology, 2014. doi: 10.1111/bph.12995. (SCI, IF: 4.842)

65.  Zhu Q, Cai W, Sha X, Ma G, Zheng Y, Shi X, Zhu Y. Quantification of leonurine, a novel potential cardiovascular agent, in rat plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study in rats[J]. Biomedical Chromatography, 2012, 26(4): 518-23. (SCI, IF: 1.723)

66.  Zhang JW, Zhou F, Wu XL, Gu Y, Ai H, Zheng YT, Li YN, Zhang XX, Hao G, Sun JG, Peng Y, and Wang GJ. 20(S)-Ginsenoside Rh2 noncompetitively inhibits P-glycoprotein in vitro and in vivo: A case for Herb-Drug interactions[J]. Drug Metabolism and Disposition, 2010, 38(12): 2179-87. (SCI, IF: 3.252)

67.  Liu L, Aa J, Wang G, Yan B, Zhang Y, Wang X, Zhao C, Cao B, Shi J, Li M, Zheng T, Zheng Y, Hao G, Zhou F, Sun J, Wu Z. Differences in metabolite profile between blood plasma and serum[J]. Analytical Biochemistry, 2010, 406(2): 105-12. (SCI, IF: 2.219)

68.  Gu Y, Wang GJ, Wu XL, Zheng YT, Zhang JW, Ai H, Sun JG, and Jia YW. Intestinal absorption mechanisms of ginsenoside Rh2: stereoselectivity and involvement of ABC transporters[J]. Xenobiotica, 2010, 40(9): 602-12. (SCI, IF: 2.199)

69.  Yan B, A J, Hao HP, Wang GJ, Zhu XX, Zha WB, Liu LS, Guan E, Zhang Y, Gu SH, Huang Q, Zheng YT. Metabonomic phenotype and identification of “heart blood stasis obstruction pattern” and “qi and yin deficiency pattern” of myocardial ischemia rat models. [J]. Science China Life Sciences, 2009, 52(11): 1081-90. (SCI, IF: 1.688)

70.  Hu XL, Zheng YZ, Sun JG, Shang LL, Wang GJ, Zhang HT. Simultaneous Quantification of Benazepril, Gliclazide and Valsartan in Human Plasma by LC–MS–MS and Application for Rapidly Measuring Protein Binding Interaction between Rhein and These Three Drugs[J]. Chromatographia, 2009, 69(9): 843-52. (SCI, IF: 1.411)

71.  Yan B, A J, Wang G, Lu H, Huang X, Liu Y, Zha W, Hao H, Zhang Y, Liu L, Gu S, Huang Q, Zheng Y, Sun J. Metabolomic investigation into variation of endogenous metabolites in professional athletes subject to strength-endurance training[J]. Journal of Applied Physiology (1985), 2009, 106(2): 531-8. (SCI, IF: 3.056)

72.  邵腾飞,郑媛婷*(通信作者),李涛,蔡卫民. K-Ras基因型对抗肿瘤药物临床疗效预测作用的研究进展[J].中国药师, 2014, 17(7): l1152-6. (核心)

73.  杨慧莹,郑媛婷,邢军芬,蔡卫民. 药物代谢毒性体外预测新方法的研究进展[J].中国药理学通报, 2013, 29(6): 748-51. (核心)

74.  邵腾飞,郑媛婷,徐佳琳,蔡卫民. 人血浆中伊立替康及其活性代谢物7-乙基-10 羟基喜树碱浓度高效液相色谱-荧光测定方法的建立[J].中国医院药学杂志, 2012, 32(1): 17-9. (核心)

75.   Guo Ma, Baojian Wu, Song Gao, Zhen Yang, Yong Ma, Ming Hu. Mutual regioselective inhibition of human UGT1A1-mediated glucuronidation of four flavonoids[J]. Mol Pharm, 2013, 10(8):2891-2903. (SCI, IF 5.841)

76.  Guo Ma, Jiayuan Lin, Weimin Cai, Bo Tan, Xiaoqiang Xiang,Ying Zhang, Peng Zhang. Simultaneous determination of bilirubin and its glucuronides in liver microsomes and recombinant UGT1A1 enzyme incubation systems by HPLC method and its application to bilirubin glucuronidation studies[J]. J Pharm Biomed Anal, 2014, 92:149-159. (SCI, IF2.997)

77.  Guo Ma, Xue-Hua Jiang, Zhuo chen, Jing Ren, Chen-Rui Li, Tai-Ming Liu. Simultaneous determination of vitexin-4″- O- glucoside and vitexin-2″-O-rhamnoside from hawthorn leaves flavonoids in rat plasma by HPLC method and its application to pharmacokinetic studies[J]. J Pharm Biomed Anal, 2007, 44:243-249. (SCI, IF 2.997)

78.  Dengfeng Tang1, Guo Ma1 (Co-first author), Luyan Zhang, Gang Chen. Graphene-epoxy composite electrode fabricated by in situ polycondensation for enhanced amperometric detection in capillary electrophoresis[J]. J Chromatogr A, 2013, 1316: 127-134.

79.  Zhu X, Zhang X, Ma G, Yan J, Wang H, Yang Q.Transport characteristics of tryptanthrin and its inhibitory effect on P-gp and MRP2 in Caco-2 cells[J]. J Pharm Pharm Sci, 2011, 14(3): 325-335.       

80.  马国,朱依谆,张鹏,蔡卫民,华蓉蓉. 我国临床药学人才培养模式探讨[J]..中国临床药学杂志, 2009, 18(5): 307-312.

81.  华蓉蓉,马国*,张鹏. 医院管理人员对临床药学工作和临床药师认知情况的调查[J].中国临床药学杂志, 2010, 19(4):226-230. 通信作者

82.  林佳媛, 张鹏, 蔡卫民,马国*.银杏叶提取物注射液中槲皮素、山柰酚、异鼠李素及其总黄酮醇苷的HPLC法测定[J].中国医药工业杂志, 2012, 43(12):1016-1019. 通信作者

83.  林佳媛, 马国*.胆红素的代谢及其调节研究进展[N].复旦学报(医学版), 2014, 41(3): 405-411. 通信作者

84.  刘备,马国*.新生儿黄疸的治疗药物研究进展[J].中国医院药学杂志, 2015, 35(16): 1515-1519. 通信作者

85.  黄文杰,蔡卫民,马国*. 上海市二、三级医疗卫生机构临床药师对临床药学工作及自身职业的认知情况调查研究[J]. 中国药房, 2016.  (in press)

86.  王芬,蔡卫民,马国*. 上海市二、三级医院医护人员对临床药学工作和临床药师认知情况的调查研究[J].中国医院药学杂志, 2016; 36(2):13-16. 

87.  洪兰,叶佩芸,叶桦.基于医药专业人员视角下的面向公众合理用药宣传现状调查[J].中国药事,2015,29(6):655-659.(核心)

88.  洪兰,叶桦,贡庆.WHO国家药品状况评估、监测和评价工具包研究及对我国的启示[J].中国药事,2015, 29(2):115-119.(核心)

89.  妥艳艳,严伟民,洪兰*(通信作者).上海市部分社区居民对家庭医生制度的认知调查[J].上海医药,2015,36(7):66-71

90.  洪兰,贡庆,叶桦.对三十个省份基本药物招标采购实施方案的分析[J].中国卫生经济,2014,7:75-78(核心)

91.  洪兰,朱俊怡.国内外药品说明书和标签管理中有关警示语的比较研究[J].中国药房,2014,25(33):3161-3163.(核心)

92.  贡庆,叶桦,洪兰*(并列通信作者).我国省级药品监管部门药品质量公告发布调查[J]. 中国药事,2014, 28(11):1182-1186.(核心)

93.  汤文璐,茅以城,洪兰*(通信作者).在药学生中开展医学基础教育的探讨[J].中国临床药学杂志,2014, 23(4):256-258.(核心)

94.  洪兰,贡庆,叶桦.我国各省基本药物招标采购制度中药品价格控制策略的比较[J].中国药房,2013,24(44):4148-4150.(核心)

95.  洪兰,王维,贡庆,叶桦.基层医疗卫生机构基本药物补偿模式的比较[J].中国药事,2013, 27(12):1237-1241.(核心)

96.  洪兰,朱烨琳,虞劲祥,马睿,叶桦.上海市基层医务工作者关于实施基本药物制度的KABP调查[J]. 中国药事,2013,27(5):467-470,478.(核心)

97.  洪兰,贡庆,姚蔚,叶桦.上海市中老年慢性病患者对药品不良反应认知的调查分析[J]. 中国药房,2011,22(12):1065-1066.(核心)

98.  洪兰,刘晓晴,叶桦.喹诺酮类药品上市后安全性评价文献的系统性分析[J].中国临床药学杂志,2010,19(5):303-306.(核心)

99.  洪兰,叶桦.美国FDA关于专业监管人才培养的启示[J].中国药事, 2010, 24(3):306-309.(核心)

100.              贡庆洪兰薛青松叶桦.对5366例药品不良反应数据的分析[J].中国药事,2011, 25(5):456-459.(核心)

101.              贡庆,洪兰,叶桦.在大学《医药伦理》课程中设置现场调查环节的尝试[J].中国医学伦理学,2014, 27(1):73-75.

102.              贡庆,洪兰,叶桦.本科生对于医药伦理通识教育核心课程的认知与态度调查[J].中国高等医学教育,2014,7: 41-42.


三、专利

1.         郑媛婷,蔡卫民,李涛,邵腾飞. 一种抗胰腺癌药物组合物及其应用、药盒和包装件.专利申请号:201310753515.4,公开号:103933046A。

2.         郑媛婷,蔡卫民,李涛,邵腾飞,周宁,杨慧莹. 一种抗肺癌药物组合物及其应用、药盒和包装件. 专利申请号:201310023598.1。

3.         郑媛婷,邵腾飞,蔡卫民. 一种预测紫杉烷类化疗药物疗效的试剂盒. 专利申请号:201310455673.1,公开号:104515839A。

4.                  郑媛婷,赵贝,蔡卫民,李涛,孙红. PI3K抑制剂与紫杉醇的药物组合物及其在制备抗肿瘤药物中的应用. 专利申请号:201510023509.2.

5.         郑媛婷,李涛,蔡卫民,孙红,赵贝. 一种治疗肿瘤的药物组合物及其制备方法. 专利申请号:201510024274.9.

6.         杨慧莹,蔡卫民,郑媛婷. 用于药物代谢及药效、毒性评价的代谢酶-水凝胶体系. 专利申请号:201310310303.9,公开号:104342427A.

7.         郁颖,庆涛,赵琛,杜婷婷,郑媛婷,石乐明. 一种对高通量RNA测序数据的质量控制方法及装置. 专利申请号:201410409210.6.

8.         赵琛、郁颖、庆涛,石乐明,一种基于高通量测序数据的计算机集群的作业调度系统.专利申请号:201410409376.8.

打印 返回